New immunotherapy plus chemotherapy before surgery for early triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies a new drug called QL1706 (an immunotherapy that helps your immune system fight cancer) combined with standard chemotherapy before surgery. The goal is to see if this combination can shrink or eliminate the tumor more effectively in early-stage triple-negative breast cancer, potentially improving your long-term outcome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have been newly diagnosed with triple-negative breast cancer (the cancer is not driven by estrogen, progesterone, or HER2).
- Your cancer is at a relatively early stage (stage I to III), and you have not yet had surgery or other treatment.
- You have at least one tumor that can be measured on a scan.
- You are in generally good physical condition (fully active or limited only in strenuous activity).
- Your heart, liver, kidney, and blood cell counts are within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
This trial tests a new immunotherapy combination with chemotherapy given before breast cancer surgery, to shrink the tumor and improve outcomes. It's for people with early-stage triple-negative breast cancer whose tumors are larger than 2 cm.
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
This trial tests a new drug combination given before surgery for early-stage, hormone receptor-positive breast cancer. It aims to see if this approach can improve outcomes for patients with high-risk features.
This trial tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy, before surgery, can improve treatment for early triple-negative breast cancer. It compares two chemotherapy approaches—one with anthracyclines and one without—to see which works better when combined with toripalimab.
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.